These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32402172)

  • 1. Teprotumumab for Active Thyroid Eye Disease. Reply.
    Douglas RS; Kahaly GJ
    N Engl J Med; 2020 May; 382(20):1959-1960. PubMed ID: 32402172
    [No Abstract]   [Full Text] [Related]  

  • 2. Teprotumumab for Active Thyroid Eye Disease.
    Roos JCP; Hyry HI; Murthy R
    N Engl J Med; 2020 May; 382(20):1959. PubMed ID: 32402171
    [No Abstract]   [Full Text] [Related]  

  • 3. Teprotumumab for Active Thyroid Eye Disease.
    Kim S; Patzek S
    N Engl J Med; 2020 May; 382(20):1958-1959. PubMed ID: 32402170
    [No Abstract]   [Full Text] [Related]  

  • 4. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.
    Bartalena L; Marcocci C; Tanda ML; Marinò M
    J Endocrinol Invest; 2022 Aug; 45(8):1603-1604. PubMed ID: 35633498
    [No Abstract]   [Full Text] [Related]  

  • 6. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Teprotumumab for the treatment of thyroid eye disease: The Holy grail, really?].
    Martel A
    J Fr Ophtalmol; 2023 Jun; 46(6):567-570. PubMed ID: 37068976
    [No Abstract]   [Full Text] [Related]  

  • 10. Teprotumumab-related Cutaneous Hypersensitivity Reactions.
    Dallalzadeh LO; Ting M; Topilow N; Robbins SL; Liu CY; Burkat CN; Korn BS; Kikkawa DO
    Ophthalmic Plast Reconstr Surg; 2023 Nov-Dec 01; 39(6):e208-e210. PubMed ID: 37656913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Teprotumumab for thyroid-associated ophthalmopathy : OPTIC].
    Gärtner R; Nitschmann S
    Internist (Berl); 2020 Nov; 61(11):1208-1210. PubMed ID: 33025123
    [No Abstract]   [Full Text] [Related]  

  • 13. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
    Hwang CJ; Nichols EE; Chon BH; Perry JD
    Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply Re: "Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease".
    Reshef ER; Marsiglia M; Bouhadjer K; Chiou CA; O'Brien-Coon D; Reinshagen KL; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):397. PubMed ID: 37413682
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of teprotumumab in thyroid eye disease.
    Greenhill C
    Nat Rev Endocrinol; 2021 Jul; 17(7):383. PubMed ID: 33953374
    [No Abstract]   [Full Text] [Related]  

  • 17. Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
    Piantanida E; Bartalena L
    J Endocrinol Invest; 2017 Aug; 40(8):885-887. PubMed ID: 28634704
    [No Abstract]   [Full Text] [Related]  

  • 18. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
    Chen KW; Phelps PO
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of teprotumumab in chronic, clinically active thyroid eye disease.
    Yu CY; Simmons BA; Pham CM; Shriver EM
    Eye (Lond); 2022 Jul; 36(7):1500-1501. PubMed ID: 34983925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.